The granulocyte-macrophage colony-stimulating factor (GM-CSF) was initially classified as a
hematopoietic growth factor. However, unlike its close relatives macrophage CSF (M-CSF) …

Immunomodulatory and immunosuppressive treatments for multiple sclerosis (MS) are
associated with an increased risk of infection, which makes treatment of this condition …

Objective To characterize the accrual of long‐term disability in a cohort of actively treated
multiple sclerosis (MS) patients and to assess whether clinical and magnetic resonance …

Objective: To investigate the safety and efficacy of rituximab in multiple sclerosis (MS).
Methods: In this retrospective uncontrolled observational multicenter study, off-label …

Monoclonal Abs against CD20 reduce the number of relapses in multiple sclerosis (MS);
commonly this effect is solely attributed to depletion of B cells. Recently, however, a subset …

A61K48/0075—Medicinal preparations containing genetic material which is inserted into
cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of …

2013-03-19 Assigned to modeRNA Therapeutics reassignment modeRNA Therapeutics
ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors …

First worldwide family litigation filed litigation Critical https://patents. darts-ip. com/? family=
45893552&utm_source= google_patent&utm_medium= platform_link&utm_campaign …

B cells play a central role in the pathogenesis in multiple sclerosis (MS), being involved in
the activation of proinflammatory T cells, secretion of proinflammatory cytokines, and …

First worldwide family litigation filed litigation Critical https://patents. darts-ip. com/? family=
48044115&utm_source= google_patent&utm_medium= platform_link&utm_campaign …